This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Tilray, Inc. (TLRY) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Tilray, Inc. (TLRY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tilray, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tilray, Inc. (TLRY) delivered earnings and revenue surprises of -90.00% and -22.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.
Tilray, Inc. (TLRY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $17.72 in the latest trading session, marking a -0.73% move from the prior day.
Marijuana Stocks To Consider Before Celebrating 420
by Daniel Laboe
In the wake of this marijuana holiday's inevitable festivities, the US house of representatives passed the SAFE Banking Act, which would give US marijuana companies access to funding from federally insured banks.
Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $17.20 in the latest trading session, marking a +1.53% move from the prior day.
Zacks Market Edge Highlights: Coinbase, Facebook, Snap, Tilray and Airbnb
by Zacks Equity Research
Zacks Market Edge Highlights: Coinbase, Facebook, Snap, Tilray and Airbnb
Should You Buy the Coinbase IPO?
by Tracey Ryniec
Coinbase is the hottest IPO of the year but history shows it could be a wild ride.
Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $19.77, moving +0.05% from the previous trading session.
Do Options Traders Know Something About Tilray (TLRY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Inside the Top-Performing ETFs of Q1
by Sweta Killa
Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $22.04, moving +1.9% from the previous trading session.
Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $27.47, marking a +1.85% move from the previous day.
Cannabis ETF (MSOS) On a High, Reaches $1B AUM Milestone
by Sweta Killa
AdvisorShares Pure US Cannabis ETF (MSOS) has been surging in popularity with its assets growing more than 40,000% in just six months.
Do Options Traders Know Something About Tilray (TLRY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Markets Break Higher; NVIDIA Beats Q4 Expectations
by Mark Vickery
NVIDIA (NVDA) beat estimates on both top and bottom lines after regular trading this afternoon.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Dow Sets New High; Tilray & Twilio Beat
by Mark Vickery
Cannabis supply giant Tilray (TLRY) is up 14% in the late market, following a 9% sell-off in regular day trading.
Tilray, Inc. (TLRY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tilray, Inc. (TLRY) delivered earnings and revenue surprises of 42.86% and 1.82%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2020 results.
Marijuana ETFs on a High on Reddit Frenzy
by Sanghamitra Saha
After promoting GameStop (GME) and Silver, Reddit's discussion has now popularized marijuana stocks like Sundial Growers (up 78.8% on Feb 10) and Tilray (up more than 50% on Feb 10).
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day
3 Stocks to Benefit From the Rapid Adoption of Marijuana
by Zacks Equity Research
The marijuana industry looks set to witness growth going forward due to wider adoption, making it prudent to look at names like Scotts Miracle-Gro (SMG), GrowGeneration (GRWG) and Tilray (TLRY)
Tilray Bought by the Reddit Crowd, Plus UBER's Q3
by Mark Vickery
Shares of the marijuana pharma company shot up another 51% Wednesday, following a +44% performance yesterday; Tilray is now up 400% in just the last month alone.
Cannabis Stocks Rise on Hopes of Federal Legalization in US
by Zacks Equity Research
Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.